When investors talk about U.S. medical device giants, Abbott Laboratories and Intuitive Surgical often come up in the same breath. But over the past eight quarters, the two industry heavyweights have been running on entirely different tracks: one winning on scale, the other winning on speed.
By raw revenue, Abbott Laboratories (NYSE: ABT) has outearned Intuitive Surgical (Nasdaq: ISRG) in every single quarter of the comparison. In the quarter ended June 30, 2026, Abbott posted roughly $12.6 billion in revenue, compared with about $2.9 billion for Intuitive — nearly a fourfold gap. Between the third quarter of 2024 and the second quarter of 2026, Abbott’s top line grew from $10.6 billion to $12.6 billion, adding about $2 billion in revenue.
Yet when it comes to growth, Intuitive Surgical is in a different league. Over the same stretch, its revenue climbed from $2.0 billion to $2.9 billion, a gain of roughly 45%, versus Abbott’s approximately 19%. That means Intuitive — despite a far smaller base and an absolute revenue gain of less than $1 billion — is expanding at a materially faster clip than its larger rival.
Both companies have notched steady quarter-over-quarter gains without any sustained decline, though their top lines have moved up and down along the way. Investors should also note a seasonal pattern: the quarter ending in March has been a soft spot for both companies, with revenue pulling back sequentially.
Abbott’s revenue engine is broad and diversified, spanning medical devices, diagnostic testing systems, nutritional formulas and generic pharmaceuticals, distributed across global healthcare networks. Recently, it entered a global licensing agreement with ALZpath to advance blood-based disease testing and reached administrative agreements to resolve specific infant formula litigation claims. In the June 2026 quarter, Abbott reported an operating margin of about 14%. As a mature large-cap, the company also offers a dividend yield of roughly 2.5%.
Intuitive Surgical, by contrast, is highly concentrated: it makes and sells robotic-assisted surgical systems, together with the specialized disposable instruments, digital diagnostic accessories and technical training services hospitals need to operate them. The company has been managing regulatory recalls involving certain surgical instrument components while observing cooled domestic procedure volumes; it also recently launched a new patient-awareness campaign. Its June-quarter operating margin came in at about 34% — a markedly more profitable profile than Abbott’s — though Intuitive does not currently pay a dividend.
The contrast illustrates a well-known investor truth: as companies get bigger, growth tends to slow. Abbott trades roughly a $10 billion quarterly revenue lead for stability and a shareholder payout; Intuitive leans on its surgical robotics franchise to sustain growth near 40% levels.
Both stocks have been under pressure lately. Over the eight-quarter window, Abbott’s total return has fallen about 17.6%, while Intuitive’s has dropped roughly 19%, with both names suffering steep losses so far this year.
For long-term investors, the key question going forward is whether the absolute revenue gap between the two companies keeps widening or starts to narrow as Intutive sustains its pace. Can the surgical robotics leader keep compounding at its current rate, or will it eventually plateau? The answers will unfold in coming reporting seasons. Both boast solid business models, recurring revenue streams and growth opportunities — but from here, their paths are likely to keep diverging.
